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Background
Programmed death-1 (PD-1) and cytotoxic T-lymphocyte
antigen-4 (CTLA-4) receptors are immune checkpoint
receptors involved in tumor immune evasion. Nivolumab
and ipilimumab are fully human monoclonal PD-1 and
CTLA-4 blocking antibodies, respectively, and have
shown clinical antitumor activity as monotherapy. In a
multicohort, phase 1 study with melanoma patients (pts),
nivolumab/ipilimumab combination produced objective
response rates (ORRs) of up to 53% (NCT01024231). We
evaluated putative predictive biomarkers for nivolumab
and ipilimumab monotherapy in the combination setting,
including tumor PD-L1 expression, absolute lymphocyte
count (ALC), peripheral blood (PB) myeloid-derived sup-
pressor cells (MDSCs), and pharmacodynamic changes in
T-cell phenotype.
Methods
An automated immunohistochemistry assay (developed
by Dako) using the 28-8 PD-L1 antibody was used to
evaluate tumor PD-L1 membrane expression in archival
FFPE specimens. ALC was measured in serial PB sam-
ples. Flow cytometry was used to characterize changes in
percentage, number, and phenotype of activated CD4+
and CD8+ T cells and MDSC.
Results
Using a cut-off of 5% tumor cell membrane staining,
37% of pts (13/35) exhibited PD-L1 expression. Nine of
22 pts (41%) with PD-L1 negative tumors and 6/13 pts
(46%) with PD-L1 positive tumors achieved an OR. ALC
increase vs baseline was not observed, but phenotypic
changes in PB T-cell subsets (increases in percentage of
CD4 and CD8 expressing HLA-DR, ICOS, and/or Ki67)
were evident. Six of 14 pts (43%) with low ALC (<1.0 at
wk 6-7) achieved an OR, vs 15/38 pts (39%) with ALC
≥1.0 at wk 6-7. Lower pretreatment percent MDSC cor-
related with higher ORR (P<0.05).
Conclusions
ORRs with nivolumab/ipilimumab combination in this
small pt subset were not associated with PD-L1 expression
or ALC, in contrast to prior observations with nivolumab
or ipilimumab monotherapy, respectively. Compared with
either therapy alone, the combination may induce an
immune response with distinct characteristics. PB and
tumor biomarkers, and their relationship to clinical activ-
ity patterns, will be further investigated in this study and
in phase 2/3 randomized studies.
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